Related Experiment Video
Updated: May 2, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Kidney cancer, version 2.2014
Robert J Motzer1, Eric Jonasch, Neeraj Agarwal
1From 1Memorial Sloan-Kettering Cancer Center; 2The University of Texas MD Anderson Cancer Center; 3Huntsman Cancer Institute at the University of Utah; 4Dana-Farber/Brigham and Women's Cancer Center; 5Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 6University of Alabama at Birmingham Comprehensive Cancer Center; 7Vanderbilt-Ingram Cancer Center; 8UC San Diego Moores Cancer Center; 9Moffitt Cancer Center; 10Stanford Cancer Institute; 11The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 12Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 13University of Colorado Cancer Center; 14City of Hope Comprehensive Cancer Center; 15Roswell Park Cancer Institute; 16Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 17Massachusetts General Hospital Cancer Center 18The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 19Fox Chase Cancer Center; 20Duke Cancer Institute; 21University of Michigan Comprehensive Cancer Center; 22UCSF Helen Diller Family Comprehensive Cancer Center; 23St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 24Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; and 25National Comprehensive Cancer Network.
Abstract:
These NCCN Guidelines Insights highlight treatment recommendations and updates specific to the management of patients with advanced non-clear cell carcinoma included in the 2014 version of the NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer.
Insights
This summary covers 2014 NCCN Guidelines for advanced non-clear cell kidney cancer. It details updated treatment recommendations for oncologists managing these complex cases.
Area of Science:
- Oncology
- Nephrology
- Clinical Practice Guidelines
Background:
- Advanced non-clear cell kidney cancer presents unique management challenges.
- The National Comprehensive Cancer Network (NCCN) provides evidence-based guidelines for cancer care.
- Regular guideline updates are crucial for incorporating new research and treatment options.
Purpose of the Study:
- To summarize key updates in the 2014 NCCN Guidelines for Kidney Cancer.
- To focus on treatment recommendations for advanced non-clear cell carcinoma.
- To provide clinicians with accessible insights into current management strategies.
Main Methods:
- Review of the 2014 NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer.
- Identification of specific recommendations for advanced non-clear cell histology.
- Synthesis of information for clinical practice insights.
Main Results:
- The 2014 guidelines include updated treatment recommendations for advanced non-clear cell kidney cancer.
- These insights highlight specific management strategies relevant to this patient population.
- The document serves as a focused summary of guideline content.
Conclusions:
- Clinicians should consult the 2014 NCCN Guidelines for current treatment approaches.
- Management of advanced non-clear cell kidney cancer benefits from adherence to updated guidelines.
- These insights facilitate the practical application of NCCN recommendations.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Chronic Kidney Disease II: Clinical Manifestations
Kidney Transplant I: Introduction
Chronic Kidney Disease I: Introduction
Kidney Structure
Chronic Kidney Disease III: Interprofessional Care

